Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: kdd999 who wrote (31079)	6/22/2015 7:31:16 PM
From: sogwap1	Read Replies (1) \| Respond to of 63284

Appreciate that, but the last Sunday in October is much longer than any of us expected. And, when does Doc & Cindy get their bonuses? soon I think, right? it's going to get bumpy.

To: kdd999 who wrote (31079)	6/22/2015 7:41:06 PM
From: sogwap1	Respond to of 63284

I went back and looked at your post- good call !

To: kdd999 who wrote (31079)	6/23/2015 12:13:55 AM
From: EMU2	Respond to of 63284

Why would this be different? Many hair splitters here.

To: kdd999 who wrote (31079)	6/23/2015 8:51:28 AM
From: Rob_StCloudFL	9 Recommendations Recommended By bobbseytwins2001 captcobra1 duwhee gaduntz73 kdd999 and 4 more members Read Replies (1) \| Respond to of 63284

Several of the posts regarding timing of eprat results with links to the UCB site caused me to look into their Phase 3 trial for brivaracetam for epilepsy. What we seemed to have learned over the last week or so is that UCB will not be bound by arbitrary timing. What I believe we have known all along is their meticulous approach to drug trials. As noted by kdd they spent considerable time analyzing the brivaracetam results. Their published findings reflect that effort. The p values showing statistical significance were less than 0.001. The studies were completed in May of 2014. Results were released in July, and regulatory filing in both the US and Europe did not occur until January of 2015. The eprat trials have taken far longer than most of us had hoped. Every step of the way seemed to drag on. But, in the end it may pay off for UCB, IMMU and stockholders for both companies. I did a cursory search to try to find UCB drug trial failures. I did not find anything off the bat. More persistent searchers on this board may be more successful. What I did find was articles and papers generally on the subject of Phase 3 trial successes and failures. Over a period of years the overall success rates have declined from about 70% to a range of 50% to 65% [pick your source of data]. The reasons for failure are mostly attributed to inadequate Phase 2 trials particularly with respect to efficacy and safety. Most of us seem to agree that UCB spent a long time on the Phase 2 trials, which yielded data sufficiently compelling for them to invest in Phase 3 trials. UCB's market cap is $12.4B - about 1/10th of players like AMGN, AZN or GSK. Thus, they are motivated to reduce the risk of failure as much as possible. And, they have a reputation for that. So, we wait! But, the good news is that our wait has nothing to do with IMMU. Frankly, I ignore the IMMU bashers in this case, because, again, it is nothing about IMMU. And, sadly, for the option holders UCB probably does not pay attention to IMMU options. If results are successful, the ultimate wait may be quite a bit longer.